JP2010536890A - パーキンソン病の治療のために有用なカテコールアミン誘導体 - Google Patents

パーキンソン病の治療のために有用なカテコールアミン誘導体 Download PDF

Info

Publication number
JP2010536890A
JP2010536890A JP2010522187A JP2010522187A JP2010536890A JP 2010536890 A JP2010536890 A JP 2010536890A JP 2010522187 A JP2010522187 A JP 2010522187A JP 2010522187 A JP2010522187 A JP 2010522187A JP 2010536890 A JP2010536890 A JP 2010536890A
Authority
JP
Japan
Prior art keywords
benzo
compound
compound according
pharmaceutically acceptable
octahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010522187A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010536890A5 (enExample
Inventor
イェルゲンセン・モルテン
バング−アンダーセン・ベンニュ
ピュシュル・アスク
メルク・ニエルス
ラーセン・ジェニファー
ウィクストレム・ホーカン・ヴィルヘルム
Original Assignee
ハー・ルンドベック・アクチエゼルスカベット
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39877715&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2010536890(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ハー・ルンドベック・アクチエゼルスカベット filed Critical ハー・ルンドベック・アクチエゼルスカベット
Publication of JP2010536890A publication Critical patent/JP2010536890A/ja
Publication of JP2010536890A5 publication Critical patent/JP2010536890A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/08—Aza-anthracenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Portable Nailing Machines And Staplers (AREA)
JP2010522187A 2007-08-31 2008-08-28 パーキンソン病の治療のために有用なカテコールアミン誘導体 Pending JP2010536890A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200701250 2007-08-31
PCT/DK2008/050215 WO2009026935A1 (en) 2007-08-31 2008-08-28 Catecholamine derivatives and prodrugs thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014021193A Division JP2014111635A (ja) 2007-08-31 2014-02-06 カテコールアミン誘導体およびそのプロドラッグ

Publications (2)

Publication Number Publication Date
JP2010536890A true JP2010536890A (ja) 2010-12-02
JP2010536890A5 JP2010536890A5 (enExample) 2011-09-22

Family

ID=39877715

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2010522187A Pending JP2010536890A (ja) 2007-08-31 2008-08-28 パーキンソン病の治療のために有用なカテコールアミン誘導体
JP2010522186A Expired - Fee Related JP5548125B2 (ja) 2007-08-31 2008-08-28 パーキンソン病の治療のために有用なカテコールアミン誘導体
JP2014021193A Pending JP2014111635A (ja) 2007-08-31 2014-02-06 カテコールアミン誘導体およびそのプロドラッグ
JP2014085192A Expired - Fee Related JP5802792B2 (ja) 2007-08-31 2014-04-17 パーキンソン病の治療のために有用なカテコールアミン誘導体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2010522186A Expired - Fee Related JP5548125B2 (ja) 2007-08-31 2008-08-28 パーキンソン病の治療のために有用なカテコールアミン誘導体
JP2014021193A Pending JP2014111635A (ja) 2007-08-31 2014-02-06 カテコールアミン誘導体およびそのプロドラッグ
JP2014085192A Expired - Fee Related JP5802792B2 (ja) 2007-08-31 2014-04-17 パーキンソン病の治療のために有用なカテコールアミン誘導体

Country Status (29)

Country Link
EP (4) EP3009437A1 (enExample)
JP (4) JP2010536890A (enExample)
KR (3) KR20100051834A (enExample)
CN (3) CN101842354A (enExample)
AR (2) AR068045A1 (enExample)
AU (2) AU2008291425B2 (enExample)
BR (2) BRPI0813456A2 (enExample)
CA (2) CA2691961C (enExample)
CL (2) CL2008002558A1 (enExample)
CO (2) CO6270232A2 (enExample)
CY (1) CY1117326T1 (enExample)
DK (1) DK2197883T3 (enExample)
EA (2) EA018413B1 (enExample)
ES (1) ES2557485T3 (enExample)
HR (1) HRP20151334T1 (enExample)
HU (1) HUE025882T2 (enExample)
IL (1) IL203080A (enExample)
MX (1) MX2010002210A (enExample)
MY (2) MY148948A (enExample)
NZ (2) NZ582379A (enExample)
PL (1) PL2197883T3 (enExample)
PT (1) PT2197883E (enExample)
RS (1) RS54470B1 (enExample)
SG (1) SG184711A1 (enExample)
SI (1) SI2197883T1 (enExample)
TW (2) TWI404702B (enExample)
UA (2) UA97989C2 (enExample)
WO (2) WO2009026935A1 (enExample)
ZA (2) ZA200909191B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022533914A (ja) * 2019-05-21 2022-07-27 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するためのカテコールアミンカルバメートプロドラッグ
JP2022533912A (ja) * 2019-05-21 2022-07-27 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI404702B (zh) * 2007-08-31 2013-08-11 Lundbeck & Co As H 兒茶酚胺衍生物和其前藥
US8067410B2 (en) 2008-06-27 2011-11-29 H. Lundbeck A/S Phenolic and catecholic amines and prodrugs thereof
EP2303851A1 (en) * 2008-06-27 2011-04-06 H. Lundbeck A/S Novel phenolic and catecholic amines and prodrugs thereof
TW201035054A (en) * 2009-02-27 2010-10-01 Lundbeck & Co As H Methods of administering (4aR, 10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol and pharmaceutical compositions thereof
TW201036949A (en) * 2009-02-27 2010-10-16 Lundbeck & Co As H Treatment of dyskinesia related disorders
US10729710B2 (en) * 2017-11-24 2020-08-04 H. Lundbeck A/S Catecholamine prodrugs for use in the treatment of Parkinson's disease
WO2020070099A1 (en) 2018-10-02 2020-04-09 H. Lundbeck A/S Administration of catecholamine prodrugs in combination with a 5-ht2b antagonist
US11130775B2 (en) * 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) * 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11104697B2 (en) * 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en) * 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US12319710B2 (en) 2019-05-21 2025-06-03 H. Lundbeck A/S Catecholamine prodrugs for use in the treatment of Parkinson's diseases
WO2020234274A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
CN114478298B (zh) * 2020-11-12 2024-09-27 成都西岭源药业有限公司 一种造影剂碘佛醇的纯化方法
EP4247793A1 (en) 2020-11-17 2023-09-27 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
CN113620760A (zh) * 2021-09-07 2021-11-09 张家口思睿凯科技有限公司 一种电子盐反应液和不饱和芳香烃类化合物的还原方法
WO2025078574A1 (en) * 2023-10-12 2025-04-17 Integrative Research Laboratories Sweden Ab NOVEL ESTERS OF 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[g]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080456A (en) * 1971-10-26 1978-03-21 Schering Aktiengesellschaft Diacylapomorphines
CH648300A5 (en) * 1979-06-22 1985-03-15 Sandoz Ag Phenanthrene derivatives and medicaments containing them
US4543256A (en) * 1982-03-17 1985-09-24 Northeastern University (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
WO1990012574A1 (en) * 1989-04-25 1990-11-01 Northeastern University Dopamine agonist compounds
JPH03163078A (ja) * 1989-08-30 1991-07-15 Sankyo Co Ltd 光学活性な縮環複素環化合物及びその製法
TW357143B (en) * 1995-07-07 1999-05-01 Novartis Ag Benzo[g]quinoline derivatives
AU7490496A (en) * 1995-11-10 1997-05-29 Novo Nordisk A/S Enantiomers of cis-benz{e}indole compounds, their preparation and utility as dopamine-d3 receptor selective agents
CN1241998A (zh) * 1996-10-30 2000-01-19 伊莱利利公司 苯并[f]喹啉酮的合成
SE0002934D0 (sv) * 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
SE0102036D0 (sv) 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
AR030357A1 (es) * 2000-08-18 2003-08-20 Lundbeck & Co As H Derivados 4 -, 5 -, 6 - y 7-indol
US20050090518A1 (en) * 2003-10-24 2005-04-28 Nastech Pharmaceutical Company Inc. Method for treating parkinson's disease using apomorphine and apomorphine prodrugs
TWI404702B (zh) * 2007-08-31 2013-08-11 Lundbeck & Co As H 兒茶酚胺衍生物和其前藥

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
JPN6013034345; Ｂｉｏｏｒｇ．　Ｍｅｄ．　Ｃｈｅｍ． １６, 20070623, ３４３８-３４４４ *
JPN6013034346; Ｅｕｒ．　Ｊ．　Ｐｈａｒｍａｃｏｌ． １０８, 1985, ９９-１０１ *
JPN6013034349; Ｅｕｒ．　Ｊ．　Ｐｈａｒｍａｃｏｌ． １０５, 1984, ３３-４７ *
JPN6013034350; Ｅｕｒ．　Ｊ．　Ｐｈａｒｍａｃｏｌ． ８５, 1982, １２５-１３２ *
JPN6013034353; Ｅｕｒ．　Ｊ．　Ｐｈａｒｍａｃｏｌ． ７３, 1981, １７５-１８８ *
JPN6013034355; Ｎｅｕｒｏｐｈａｒｍａｃｏｌｏｇｙ ２３, 1984, １０２５-１０３１ *
JPN6013034358; Ｊ．　Ｈｅｔｅｒｏｃｙｃｌｉｃ　Ｃｈｅｍ． １７, 1980, １６３３-１６３６ *
JPN6013034360; Ｊ．　Ｍｅｄ．　Ｃｈｅｍ． ２３, 1980, １-５ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022533914A (ja) * 2019-05-21 2022-07-27 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するためのカテコールアミンカルバメートプロドラッグ
JP2022533912A (ja) * 2019-05-21 2022-07-27 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
JP7562562B2 (ja) 2019-05-21 2024-10-07 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
JP7696829B2 (ja) 2019-05-21 2025-06-23 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するためのカテコールアミンカルバメートプロドラッグ

Also Published As

Publication number Publication date
UA98804C2 (ru) 2012-06-25
KR20150115963A (ko) 2015-10-14
CA2691961A1 (en) 2009-03-05
UA97989C2 (uk) 2012-04-10
PT2197883E (pt) 2016-02-02
AU2008291425A1 (en) 2009-03-05
JP2014148528A (ja) 2014-08-21
WO2009026934A1 (en) 2009-03-05
CN107253956A (zh) 2017-10-17
BRPI0815894A2 (pt) 2015-02-24
CA2691961C (en) 2013-12-17
EP2197883A1 (en) 2010-06-23
JP5548125B2 (ja) 2014-07-16
ES2557485T3 (es) 2016-01-26
MY179527A (en) 2020-11-10
JP2010536889A (ja) 2010-12-02
EP3009437A1 (en) 2016-04-20
NZ583551A (en) 2012-07-27
CL2008002564A1 (es) 2009-07-17
SI2197883T1 (sl) 2016-01-29
EA200971107A1 (ru) 2010-06-30
CO6260082A2 (es) 2011-03-22
CY1117326T1 (el) 2017-04-26
TW200914426A (en) 2009-04-01
ZA201001422B (en) 2011-06-29
CN101842354A (zh) 2010-09-22
CO6270232A2 (es) 2011-04-20
NZ582379A (en) 2011-08-26
EA201070327A1 (ru) 2010-08-30
PL2197883T3 (pl) 2016-03-31
AU2008291426B2 (en) 2013-01-31
RS54470B1 (sr) 2016-06-30
KR101597367B1 (ko) 2016-02-24
HUE025882T2 (en) 2016-04-28
JP2014111635A (ja) 2014-06-19
SG184711A1 (en) 2012-10-30
CA2697688A1 (en) 2009-03-05
KR20100051834A (ko) 2010-05-18
AU2008291425B2 (en) 2012-12-06
WO2009026935A1 (en) 2009-03-05
HRP20151334T1 (hr) 2016-01-01
JP5802792B2 (ja) 2015-11-04
MX2010002210A (es) 2010-03-17
KR20100046111A (ko) 2010-05-06
CL2008002558A1 (es) 2009-08-07
TW200911752A (en) 2009-03-16
IL203080A (en) 2014-11-30
BRPI0813456A2 (pt) 2014-12-23
AU2008291426A1 (en) 2009-03-05
DK2197883T3 (en) 2016-01-11
EP2662358A1 (en) 2013-11-13
EP2197883B1 (en) 2015-11-18
ZA200909191B (en) 2011-03-30
CN101687878A (zh) 2010-03-31
AR068045A1 (es) 2009-10-28
EP2195291A1 (en) 2010-06-16
MY148948A (en) 2013-06-14
AR068044A1 (es) 2009-10-28
EA018413B1 (ru) 2013-07-30
TWI404702B (zh) 2013-08-11
EA018011B1 (ru) 2013-04-30

Similar Documents

Publication Publication Date Title
JP5548125B2 (ja) パーキンソン病の治療のために有用なカテコールアミン誘導体
US8129530B2 (en) Catecholamine derivatives and prodrugs thereof
HK1237782A (en) Catecholamine derivatives useful for the treatment of parkinson’s disease and method of preparing the same
HK1237782A1 (en) Catecholamine derivatives useful for the treatment of parkinson’s disease and method of preparing the same
US20120196889A1 (en) Catecholamine derivatives and prodrugs thereof
HK1148737A (en) Catecholamine derivatives and prodrugs thereof
HK1142072A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
HK1191333A (en) Catecholamine derivatives and prodrugs thereof
AU2013203089A1 (en) Catecholamine derivatives and prodrugs thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110803

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110803

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130806

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20130819

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20130821

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131008

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140610